Tiziana Life Sciences

Today We Announced Positive Results from Ozempic and Nasal Anti-CD3 Combination Study. · Nasal anti-CD3 in combination with Ozempic demonstrates synergistic effects in promoting liver homeostasis in obesity model. · The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders. $TLSA #Ozempic #GLP1 #Foralumab #AntiCD3 #Nasal #Intranasal Selma Boulenouar Howard Weiner https://lnkd.in/eH2d9b2j

Good write up from BBC Future about the cells that protect your brain (Microglia) could also be behind some chronic diseases – including Alzheimer's. Intranasal Foralumab has been shown to reduce microglia activation in patients with Multiple Sclerosis. MS Phase 2 is underway and Alzheimer's Disease soon. $TLSA https://lnkd.in/egACJdcP

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health (NIH) to Study Anti-CD3 in Alzheimer’s Disease. $TLSA #intranasal #foralumab #Alzheimers #AlzheimersDisease #award https://lnkd.in/g-Cwq9Xw

Tiziana Life Sciences Appoints Ivor Elrifi as New Chief Executive Officer. Ivor has extensive experience in advising clients on strategic transactional work and regularly counsels’ clients with respect to investments, business development and mergers and acquisitions, including acquisition transactions involving Novartis, Eli Lilly, Biogen and Astellas. Welcome to the team Ivor! $TLSA #foralumab #MS #Alzheimers #SPMS #ALS https://lnkd.in/emr6v235

Today we announced that we have regained compliance with the Nasdaq minimum listing requirement for continued listing on the Nasdaq Capital Market exchange. Consequently, a scheduled hearing before the Hearings Panel has been cancelled. The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market. $TLSA #Nasdaq Nasdaq Nasdaq Exchange https://lnkd.in/eSB9yjYa

Big news announcement today. The FDA has granted Fast Track Designation to intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis. #SPMS #MultipleSclerosis #Clinicaltrial $TLSA FDA https://lnkd.in/gwsFbK5m

Today Gabriele Cerrone, Chairman and CEO of Tiziana Life Sciences announced that we have received $3.2m of Non Dilutive funding and provided an exciting update on the progress of the company. Thank you Proactive for the interview $TLSA https://lnkd.in/esNVQmZd

Today we have announced that we are to dose the first patient with moderate Alzheimer's disease with intranasal foralumab under a new expanded access program allowed by the FDA. We also look forward to commencing our phase 2 trial in early symptomatic AD. #Alzheimers #AD #Microglia https://lnkd.in/eYvedWWi

We have created an animation of the MoA of Intranasal Foralumab and it's effect on microglia in the brain of a patient with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The PET scan shown in the animation is from an actual patient in our expanded access program after 6 months of treatment. #MultipleSclerosis #MS #SPMS #PIRA $TLSA https://lnkd.in/eFDRqZiB

Today we have announced that the FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis. $TLSA #MultipleSclerosis #MS #SPMS #Foralumab #FDA https://lnkd.in/e7NcdTry